Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-10-30 Director's Dealing
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Appendix 3Y - John Van Der Wielen 2 pages 218.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change (on-market purchase), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3849 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement.
2025-10-30 English
Appendix 3Y - Michael McNulty 2 pages 217.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired and disposed, nature of interest, and dates. This is a clear report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 3717 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2025-10-30 English
HK Distributor Signed as Remplir Expands in the Asian Market 3 pages 631.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the appointment of an exclusive distributor for a medical device product in Hong Kong as part of the company's Asian commercialisation strategy. It discusses market expansion, distributor appointments, and strategic plans but does not contain financial statements, earnings data, or regulatory filings. The content is focused on a business update regarding distribution and commercial strategy rather than financial results or governance changes. It is not a report, earnings release, or regulatory filing but a corporate announcement about commercial activities and partnerships. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to updates on company commercial activities and strategic partnerships that impact capital deployment and market expansion.
2025-10-28 English
Application for quotation of securities - OCC 8 pages 21.1KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from Orthocell Limited regarding the application for quotation of newly issued securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, issue dates, and references previous announcements such as Appendix 3B and Appendix 3G related to the securities issuance. The document is procedural and regulatory in nature, focusing on the listing and quotation of shares rather than financial results, management changes, or other report types. It does not contain financial statements or management discussion but is a formal regulatory filing to notify the exchange and market of the securities quotation application. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like capital changes (SHA) or share issues (POS) because it is specifically an application for quotation rather than the issuance itself or a capital change announcement. The document length (6694 characters) and content confirm it is not a brief announcement but a detailed regulatory form. Therefore, the best classification is Regulatory Filings (RNS).
2025-10-23 English
Cleansing Notice 2 pages 670.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares as part of a capital raising. It details the compliance with relevant sections of the Act and provides information about the share issue without disclosure under Part 6D.2. The content focuses on the announcement of a capital raising event and the legal notice associated with it, rather than providing financial statements or detailed financial analysis. The document length is 4712 characters, which is relatively short and consistent with a regulatory announcement. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2025-10-23 English
Notification regarding unquoted securities - OCC 10 pages 27.2KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities, including options issued as part of fees for acting as lead manager to a placement. It references previous announcements (Appendix 3B) related to securities issuance and provides specifics on the number, type, and terms of securities issued. The content is focused on the notification of securities issuance rather than a full financial report or earnings release. This matches the description of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document is lengthy and detailed, consistent with a formal notification of securities issuance rather than a brief announcement or a report publication notice.
2025-10-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.